We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $3.37B
This Fund
S&P 500
This Quarter Est. Return
-1.53%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$105M
Cap. Flow
-$52.6M
Cap. Flow %
-4.16%
Top 10 Hldgs %
60.92%
Holding
343
New
11
Increased
61
Reduced
233
Closed
34

Top Buys

Rank Stock Value
1
PDD icon
Pinduoduo
PDD
+$51.8M
2
BEKE icon
KE Holdings
BEKE
+$31M
3
TSM icon
TSMC
TSM
+$10.9M
4
BZ icon
Kanzhun
BZ
+$6.35M
5
IQ icon
iQIYI
IQ
+$4.37M

Top Sells

Rank Stock Value
1
TME icon
Tencent Music
TME
+$39.2M
2
TCOM icon
Trip.com Group
TCOM
+$19.3M
3
MRVL icon
Marvell Technology
MRVL
+$12M
4
WB icon
Weibo
WB
+$7.99M
5
JOYY
JOYY Inc
JOYY
+$7.61M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 37.28%
2 Technology 32.43%
3 Communication Services 9.6%
4 Healthcare 8.37%
5 Real Estate 6.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
151
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$425K 0.03%
11,760
+1,913
+19% +$78.8K
BMRN icon
152
BioMarin Pharmaceuticals
BMRN
$11.5B
$424K 0.03%
4,889
+621
+15% +$58.4K
PTGX icon
153
Protagonist Therapeutics
PTGX
$8.75B
$424K 0.03%
15,354
+6,641
+76% +$166K
RLAY icon
154
Relay Therapeutics
RLAY
$4.02B
$423K 0.03%
33,708
+8,516
+34% +$106K
PTCT icon
155
PTC Therapeutics
PTCT
$6.37B
$422K 0.03%
10,387
+1,655
+19% +$81K
INSM icon
156
Insmed
INSM
$23.2B
$421K 0.03%
19,953
-1,526
-7% -$29K
NTLA icon
157
Intellia Therapeutics
NTLA
$1.5B
$421K 0.03%
10,330
-452
-4% -$18.3K
ABT icon
158
Abbott
ABT
$180B
$417K 0.03%
3,826
-414
-10% -$44.1K
IRWD icon
159
Ironwood Pharmaceuticals
IRWD
$611M
$415K 0.03%
38,989
+3,670
+10% +$39.4K
TVTX icon
160
Travere Therapeutics
TVTX
$5.33B
$412K 0.03%
26,794
+8,262
+45% +$150K
VIR icon
161
Vir Biotechnology
VIR
$1.47B
$411K 0.03%
16,762
-319
-2% -$8.01K
CRSP icon
162
CRISPR Therapeutics
CRSP
$4.58B
$409K 0.03%
7,294
-1,642
-18% -$93.2K
ETNB
163
DELISTED
89bio
ETNB
$409K 0.03%
21,604
+3,464
+19% +$60.8K
TGTX icon
164
TG Therapeutics
TGTX
$8.58B
$404K 0.03%
16,266
-11,162
-41% -$288K
ENPH icon
165
Enphase Energy
ENPH
$4.84B
$401K 0.03%
2,395
-289
-11% -$51.6K
RARE icon
166
Ultragenyx Pharmaceutical
RARE
$2.65B
$401K 0.03%
8,693
-1,271
-13% -$59K
SRPT icon
167
Sarepta Therapeutics
SRPT
$1.66B
$401K 0.03%
3,499
+815
+30% +$105K
MORF
168
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$401K 0.03%
+6,991
New +$365K
PCAR icon
169
PACCAR
PCAR
$69.6B
$400K 0.03%
4,776
-851
-15% -$63K
IOVA icon
170
Iovance Biotherapeutics
IOVA
$2.23B
$399K 0.03%
56,609
-5,579
-9% -$39.9K
AKRO
171
DELISTED
Akero Therapeutics
AKRO
$397K 0.03%
8,510
-830
-9% -$38K
AEP icon
172
American Electric Power
AEP
$73.7B
$396K 0.03%
4,705
-835
-15% -$73.8K
ANET icon
173
Arista Networks
ANET
$219B
$396K 0.03%
9,764
-924
-9% -$35.7K
ABNB icon
174
Airbnb
ABNB
$83.7B
$395K 0.03%
3,080
-562
-15% -$65.7K
DNLI icon
175
Denali Therapeutics
DNLI
$3.67B
$394K 0.03%
13,361
-1,258
-9% -$35.4K
5 6
7
8 9

Similar funds

VFCM
Valley Forge Capital Management Miami, Florida $3.38B AUM 15.93% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
DIA
Dana Investment Advisors Waukesha, Wisconsin $3.35B AUM 29.65% 1-Year Est. Return
5NCM
59 North Capital Management Houston, Texas $3.35B AUM 22.14% 1-Year Est. Return
TAM
Troy Asset Management London, United Kingdom $3.35B AUM 11.7% 1-Year Est. Return
CS
CapitalatWork SA Auderghem $3.35B AUM
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
QCG
Quadrant Capital Group Cincinnati, Ohio $3.34B AUM 29.16% 1-Year Est. Return

E Fund Management's Q2 2023 Portfolio in Review

As of Q2 2023, E Fund Management held 343 positions worth $1.26B, down 7.7% from $1.37B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

E Fund Management withdrew a net $52.6M in Q2 2023, closing 34 positions and reducing 233 holdings. Its most notable exit was Trip.com Group, an estimated $19.3M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 37% of assets, up from 36% a quarter earlier, followed by Technology and Communication Services.

Against the trend, E Fund Management opened a new position in Datadog worth $881K.

  • E Fund Management's largest Q2 2023 buy was Datadog: 8,960 shares worth $881K.
  • E Fund Management added most to Pinduoduo in Q2 2023, an estimated $51.8M increase.
  • E Fund Management's biggest Q2 2023 reduction was Tencent Music, cutting an estimated $39.2M.
  • E Fund Management fully exited Trip.com Group in Q2 2023, selling an estimated $19.3M.
  • E Fund Management's ten largest holdings make up 61% of its $1.26B portfolio in Q2 2023.
  • E Fund Management opened 11 new positions and closed 34 in Q2 2023.
  • E Fund Management's portfolio value fell 7.7% quarter-over-quarter to $1.26B.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.